The health systems will serve as recruiting centers and partners in the second phase of the validation stage of the study, named DeCODe. Digital health company PhysIQ is leading the study, which aims to identify the earliest signals of an inflammatory response specific to an individual who has COVID-19, according to the May 25 news release.
Developing the biomarker also may provide early detection of a rapid clinical decompensation in high-risk COVID-19 patients.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
